Morgan Stanley’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.2M | Sell |
913,893
-165,578
| -15% | -$8.43M | ﹤0.01% | 2154 |
|
|
2025
Q4 | $53.6M | Buy |
1,079,471
+324,154
| +43% | +$15.8M | ﹤0.01% | 2014 |
|
|
2025
Q3 | $36.1M | Buy |
755,317
+61,565
| +9% | +$2.48M | ﹤0.01% | 2306 |
|
|
2025
Q2 | $21.9M | Buy |
693,752
+43,914
| +7% | +$1.41M | ﹤0.01% | 2706 |
|
|
2025
Q1 | $21.3M | Sell |
649,838
-27,829
| -4% | -$986K | ﹤0.01% | 2634 |
|
|
2024
Q4 | $24.5M | Sell |
677,667
-48,446
| -7% | -$1.71M | ﹤0.01% | 2567 |
|
|
2024
Q3 | $22.6M | Buy |
726,113
+55,546
| +8% | +$1.73M | ﹤0.01% | 2681 |
|
|
2024
Q2 | $17.9M | Buy |
670,567
+20,341
| +3% | +$590K | ﹤0.01% | 2783 |
|
|
2024
Q1 | $22.2M | Sell |
650,226
-796,484
| -55% | -$23.7M | ﹤0.01% | 2585 |
|
|
2023
Q4 | $41.9M | Buy |
1,446,710
+918,131
| +174% | +$24.3M | ﹤0.01% | 2643 |
|
|
2023
Q3 | $14.6M | Sell |
528,579
-27,319
| -5% | -$832K | ﹤0.01% | 2772 |
|
|
2023
Q2 | $16.7M | Buy |
555,898
+15,013
| +3% | +$525K | ﹤0.01% | 2651 |
|
|
2023
Q1 | $19.6M | Sell |
540,885
-189,558
| -26% | -$7.29M | ﹤0.01% | 2452 |
|
|
2022
Q4 | $26.1M | Buy |
730,443
+214,709
| +42% | +$7.46M | ﹤0.01% | 2078 |
|
|
2022
Q3 | $17.5M | Buy |
515,734
+41,705
| +9% | +$1.36M | ﹤0.01% | 2348 |
|
|
2022
Q2 | $13.7M | Buy |
474,029
+241,325
| +104% | +$6.91M | ﹤0.01% | 2715 |
|
|
2022
Q1 | $7.52M | Sell |
232,704
-45,348
| -16% | -$1.39M | ﹤0.01% | 3242 |
|
|
2021
Q4 | $8.11M | Buy |
278,052
+53,295
| +24% | +$1.62M | ﹤0.01% | 3169 |
|
|
2021
Q3 | $6M | Sell |
224,757
-38,372
| -15% | -$1.03M | ﹤0.01% | 3479 |
|
|
2021
Q2 | $8.1M | Buy |
263,129
+68,458
| +35% | +$2.1M | ﹤0.01% | 3241 |
|
|
2021
Q1 | $5.1M | Sell |
194,671
-33,890
| -15% | -$948K | ﹤0.01% | 3392 |
|
|
2020
Q4 | $5.75M | Sell |
228,561
-175,476
| -43% | -$3.78M | ﹤0.01% | 3101 |
|
|
2020
Q3 | $8.42M | Sell |
404,037
-215,789
| -35% | -$4.9M | ﹤0.01% | 2181 |
|
|
2020
Q2 | $14.7M | Sell |
619,826
-522,283
| -46% | -$11.5M | ﹤0.01% | 1638 |
|
|
2020
Q1 | $20.5M | Buy |
1,142,109
+67,945
| +6% | +$1.43M | 0.01% | 1255 |
|
|
2019
Q4 | $25.5M | Buy |
1,074,164
+728,785
| +211% | +$17.7M | 0.01% | 1448 |
|
|
2019
Q3 | $9.49M | Buy |
345,379
+24,106
| +8% | +$714K | ﹤0.01% | 2185 |
|
|
2019
Q2 | $10.6M | Sell |
321,273
-67,875
| -17% | -$2.33M | ﹤0.01% | 2092 |
|
|
2019
Q1 | $13.6M | Sell |
389,148
-150,051
| -28% | -$5.58M | ﹤0.01% | 1742 |
|
|
2018
Q4 | $17.9M | Buy |
539,199
+151,411
| +39% | +$6.51M | 0.01% | 1558 |
|
|
2018
Q3 | $19.5M | Sell |
387,788
-89,009
| -19% | -$4.4M | ﹤0.01% | 1719 |
|
|
2018
Q2 | $28.5M | Buy |
476,797
+263,559
| +124% | +$13.7M | 0.01% | 1307 |
|
|
2018
Q1 | $9.77M | Sell |
213,238
-13,508
| -6% | -$564K | ﹤0.01% | 2365 |
|
|
2017
Q4 | $9.04M | Buy |
226,746
+8,400
| +4% | +$332K | ﹤0.01% | 2499 |
|
|
2017
Q3 | $8.73M | Sell |
218,346
-192,380
| -47% | -$8.33M | ﹤0.01% | 2414 |
|
|
2017
Q2 | $17.7M | Buy |
410,726
+61,451
| +18% | +$2.19M | 0.01% | 1641 |
|
|
2017
Q1 | $10.9M | Sell |
349,275
-160,556
| -31% | -$4.3M | ﹤0.01% | 2103 |
|
|
2016
Q4 | $12.9M | Buy |
509,831
+176,890
| +53% | +$3.95M | ﹤0.01% | 1987 |
|
|
2016
Q3 | $8.23M | Sell |
332,941
-211,519
| -39% | -$4.79M | ﹤0.01% | 2186 |
|
|
2016
Q2 | $11.1M | Sell |
544,460
-20,024
| -4% | -$355K | ﹤0.01% | 1903 |
|
|
2016
Q1 | $8.61M | Sell |
564,484
-11,610
| -2% | -$151K | ﹤0.01% | 1990 |
|
|
2015
Q4 | $7.74M | Buy |
576,094
+138,608
| +32% | +$2.14M | ﹤0.01% | 2234 |
|
|
2015
Q3 | $6.14M | Buy |
437,486
+56,190
| +15% | +$1.04M | ﹤0.01% | 2462 |
|
|
2015
Q2 | $6.47M | Buy |
381,296
+343,265
| +903% | +$4.89M | ﹤0.01% | 2563 |
|
|
2015
Q1 | $460K | Sell |
38,031
-151,534
| -80% | -$1.43M | ﹤0.01% | 4713 |
|
|
2014
Q4 | $1.57M | Buy |
189,565
+134,992
| +247% | +$1.13M | ﹤0.01% | 3755 |
|
|
2014
Q3 | $475K | Sell |
54,573
-19,401
| -26% | -$175K | ﹤0.01% | 4605 |
|
|
2014
Q2 | $810K | Sell |
73,974
-231,903
| -76% | -$2.07M | ﹤0.01% | 4224 |
|
|
2014
Q1 | $2.73M | Buy |
305,877
+158,962
| +108% | +$1.46M | ﹤0.01% | 3153 |
|
|
2013
Q4 | $1.11M | Buy |
146,915
+87,541
| +147% | +$612K | ﹤0.01% | 3858 |
|
|
2013
Q3 | $435K | Sell |
59,374
-4,339
| -7% | -$29.1K | ﹤0.01% | 4427 |
|
|
2013
Q2 | $410K | Buy |
+63,713
| New | +$375K | ﹤0.01% | 4397 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Morgan Stanley's SUPN Position: Q1 2026 in Review
Morgan Stanley reduced its Supernus Pharmaceuticals (SUPN) stake by 15% in Q1 2026, selling an estimated $8.43M and leaving 913,893 shares worth $47.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.
Morgan Stanley first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $53.6M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Morgan Stanley held 913,893 shares of Supernus Pharmaceuticals worth $47.2M as of Q1 2026.
- Morgan Stanley sold 165,578 Supernus Pharmaceuticals shares in Q1 2026, an estimated $8.43M.
- Supernus Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2154 holding.
- Morgan Stanley first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Supernus Pharmaceuticals position peaked at $53.6M in Q4 2025.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.